Scholars Central

Conference abstract

An overview of the recent advances in the treatment of Parkinson?s disease

Authors: Swetha E S

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Parkinson?s Disease (PD) is the most common neurodegenerative condition. This chronic and progressive disorder is characterised by profound and selective loss of nigrostriatal dopamineric neurons. Nowadays, the disease trends have shifted from communicable to non-communicable and age related diseases. Movement disorders are one amongst them. PD constitutes about 5-60% of the movement disorders varying according to geographical regions and age. Along with classical symptoms of motor impairments involving resting tremors, bradykinesia, postural instability and rigidity, various spectrums of non motor symptoms such as hypophonia, dysphonia, drooling, autonomic dysfunction, dementia and depression are also seen. Both genetic susceptibility and the environmental factors have a combined role in the etiology of PD. At least 10 single gene mutations have been identified. Recently, mitochondrial DNA defects corresponding to complex I abnormality, oxidative damage and ubiquitin proteasome system also have been identified in the pathogenensis of PD. The medications which are used at present although target dopaminergic system, provide only symptomatic relief. Most of them also produce clinical fluctuations as seen with levodopa. None of them halt the progression of the neuronal degeneration. The major hurdle in this regard is the lack of understanding the disease process leading to the death of dopaminergic neurons. In the last decade at least 5 drugs have been approved to treat PD. Presently there are about 37drugs in the pipeline, 23 of them to treat PD, 11 of them to treat the related conditions. PD has been a strong area of research in the field of drug development.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Pharmacovigilance
  • SubjectPharmaceutical Sciences
  • BylineArticles whose byline prints “Swetha E S”